Marked response to memantine in refractory chronic migraine
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To the Editor, Refractory chronic migraine remains a therapeutic challenge, often resistant to conventional prophylactic medications and even advanced interventions like vagus nerve stimulation. Glutamatergic neurotransmission, especially through N-methyl-D-aspartate (NMDA) receptors, has been implicated in migraine chronification.[1] Memantine, a low-affinity uncompetitive NMDA receptor antagonist has theoretical neuroprotective and antisensitization properties,[2] therefore a possible option for pain disorders. We herein present a case of marked clinical response to memantine in a patient with treatment-refractory migraine, with emphasis on speculative involved mechanisms. Case Presentation A 57-year-old male with chronic uncontrolled migraine for the last 3 decades was evaluated due to clinical deterioration in the outpatient clinic. Over the preceding 8 months, migraine frequency increased from approximately two attacks per week to four–five attacks per week, characterized by severe unilateral throbbing pain, visual aura described as scintillating scotomas, and nausea, with attacks lasting approximately 3 h. After the attacks, the patient complained of fatigue and cognitive slowing that persisted for several hours. The patient reported using acute medication only in extreme situations, predominantly long-acting triptans, frovatriptan, or naratriptan, and did not fulfill diagnostic criteria for medication-overuse headache. The Migraine Disability Assessment (MIDAS) was 23, consistent with severe migraine-related disability. Except for episodic insomnia and mild anxiety, the patient had no clinically relevant comorbidities. He had failed multiple preventive therapies in the past, including beta-blockers, flunarizine, topiramate, valproate, tricyclics, selective serotonin reuptake inhibitors, and onabotulinumtoxinA. Five years earlier, vagus nerve stimulator implantation led to partial improvement, with remission of aura, a decrease in the frequency of migraine from daily episodes to 2 episodes per week, and an improved MIDAS score to 11 (moderate disability). At the time of consultation, the patient was medicated with propranolol (120 mg/day) and amitriptyline (75 mg/day) without meaningful response. Amitriptyline was discontinued and replaced by topiramate up to 300 mg/day, followed by onabotulinumtoxinA, without improvement after 2 months. While waiting for the response of the Pharmaceutic Commission to start fremanezumab, off-label memantine was initiated at 5 mg/day, titrated over several weeks to 20 mg/day. He progressively improved, and at the last visit with ten months of treatment, the patient reported less than 3 migraine attacks per month, often without aura, fatigue, or cognitive manifestations, and responding promptly to naproxen and nasal zolmitriptan. Topiramate was discontinued. The patient also reported marked improvement in quality of life; the MIDAS score was 7 (mild disability). Memantine was well tolerated, with no cognitive, vestibular, or neuropsychiatric adverse effects after 15 months. Comment It is unknown why patients with migraine have different responses to different prophylactic medications. Resistant and refractory migraine most likely involves alterations in sensory processing and neurotransmitter systems. Increased glutamatergic transmission is one of the main drives of central sensitization, which is a potential mechanism leading to resistance to treatments.[3] Multiple hypothetical mechanisms have been suggested to account for the potential therapeutic effects of memantine in migraine [Figure 1].Figure 1: Conceptual illustration of proposed mechanisms by which memantine may modulate glutamatergic signaling and central sensitization in refractory chronic migraineMemantine binds open NMDA channels with low affinity and rapid off-rate, blocking excessive activation while sparing normal synaptic transmission. By limiting calcium influx through extrasynaptic NMDA receptors, it may reduce cortical spreading depression (CSD) and thalamic sensitization, which are the neural basis of chronic migraine.[4] CSD is characterized by a slowly propagating wave of neuronal and glial depolarization followed by prolonged cortical suppression, primarily driven by excessive glutamatergic transmission.[3,4] Beyond producing aura symptoms, CSD can activate the trigeminovascular system through the release of inflammatory mediators, thereby triggering migraine headache.[3,4] Recurrent CSD episodes may also promote central and thalamocortical sensitization, contributing to migraine recurrence and chronification, as observed in our patient. Evidence supporting memantine in migraine prevention remains limited. A meta-analysis demonstrated that memantine, compared to placebo, in patients with migraine was associated with a reduction of attack frequency and MIDAS score.[4] To date, the Canadian Headache Society guidelines mention memantine as a possible prophylactic option based on limited evidence.[5] It is noteworthy that ketamine, owing to its glutamate-modulating properties, has emerged as a potential therapeutic alternative for patients with refractory migraine.[6] Despite the temporal association between memantine initiation and sustained improvement, the possibility of confounding factors, such as delayed effects of prior therapies and the natural variability of migraine history, cannot be excluded. The patient’s dramatic clinical improvement after exhausting standard treatments and vagal neuromodulation suggests a dominant role in glutamatergic hyperexcitability and central sensitization in his migraine pathophysiology. This case provides anecdotal but clinically meaningful support for memantine use in refractory chronic migraine after failure of multiple pharmacologic and neuromodulatory therapies. Controlled studies are required to define efficacy, safety, and patient selection. Author contributions HN and SF drafted the manuscript; SR edited it. All authors reviewed and approved the final version. Ethical policy and institutional review board statement Not applicable. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Data availability statement Data sharing is not applicable to this article as no datasets were generated and/or analyzed during the current study. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Fields of Study & Subjects
Migraine and Headache Studies
Pain Mechanisms and Treatments
Temporomandibular Joint Disorders
Publication details
- Journal / source
- Brain Circulation
- Volume
- 12
- Issue
- 2
- Pages
- 195–197
- Publication date
- 30 March 2026
- Language
- EN